Stereoelectroencephalography in the Presurgical Evaluation of Drug–Resistant Epilepsy: Retrospective Analysis of Clinical Efficacy and Safety in 71 Procedures

Why It Matters

The study validates SEEG as a safe, high‑precision tool that enhances seizure‑focus localization and expands minimally invasive treatment options, potentially improving surgical success rates for drug‑resistant epilepsy.

Key Takeaways

• SEEG confirmed seizure focus hypothesis in 85% of cases.
• RF‑TC yielded 73% seizure improvement at 12 months.
• Permanent neurological deficit occurred in only 1% of patients.
• Favorable Engel I‑II outcomes reached 70% after resection.
• Complication rate remained at 20%, mostly minor radiological findings.

Pulse Analysis

Drug‑resistant epilepsy affects roughly 30 % of the 3.4 million Americans living with seizures, and surgical intervention remains the only curative option for many. Traditional non‑invasive tools such as scalp EEG and MRI often leave the epileptogenic zone ambiguous, prompting clinicians to turn to stereoelectroencephalography (SEEG). By implanting depth electrodes directly into suspected cortical regions, SEEG delivers high‑resolution, three‑dimensional electrophysiological data that can pinpoint seizure onset with millimetric precision. This granular insight not only refines patient selection for resective surgery but also opens pathways for minimally invasive therapies.

The recent retrospective series of 71 patients illustrates SEEG’s practical impact. Eighty‑five percent of cases confirmed the pre‑implantation hypothesis, and more than half of the cohort underwent SEEG‑guided radiofrequency thermocoagulation (RF‑TC). Among those treated, 73 % experienced seizure reduction at one year, while resective surgery following SEEG yielded Engel class I‑II outcomes in roughly 70 % of patients. Complications were limited to a 20 % rate, predominantly minor radiological changes, and permanent neurological injury occurred in only 1 % of cases, underscoring the technique’s safety profile.

These findings are reshaping epilepsy surgery programs across the United States. Hospitals that integrate SEEG can reduce the number of futile craniotomies, lower overall treatment costs, and improve quality‑adjusted life years for patients. Moreover, the adjunctive use of RF‑TC offers a less invasive alternative for individuals unsuitable for extensive resections, expanding the therapeutic arsenal. As reimbursement models evolve to reward value‑based outcomes, the demonstrated efficacy and low morbidity of SEEG are likely to drive broader adoption and stimulate further research into combined electrophysiological‑guided interventions.